SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GregorioAllegri who wrote (2913)11/2/2013 12:01:24 AM
From: Biomaven  Read Replies (2) of 4474
 
But nilotinib clearly has the same effects - read the Kim paper. That paper states that in one trial:

35.7% receiving nilotinib as second-line therapy developed PAOD (peripheral artery occlusive disease).

Granted the VEGFR2 block might add to the issue, but there has to be something that both pona and nilotinib hits that is doing this.

I do agree that pona's future lies only in T315i/ true third line in CML, and perhaps GIST and medullary thyroid.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News